摘要
现在有许多治疗严重哮喘的生物疗法。为了评估哪种方法对哪个病人最有效,我们需要制定反应的定义。这篇叙述性综述旨在捕捉严重哮喘患者对生物治疗无反应和有反应的看法。从创建到2021年9月,对四个书目数据库进行了搜索。在患者代表的参与下检索灰色文献。采用专题方法进行综合。没有定性研究专门探讨重度哮喘患者对生物疗法的反应。包括3篇论文和1篇已发表的哮喘患者访谈。相关灰色文献来自在线论坛、博客和社交媒体网站。在减轻疾病和治疗负担方面,成年患者对生物疗法有积极反应。 Both were multifaceted. Some patients experienced reduced benefit from biological therapy over time. There was a group of patients who described a limited response or non-response to biological therapy. This was framed within the context of continuing hospitalisation and oral corticosteroid treatment. The speed of onset of benefit was felt to be important by some. Definitions of non-response and response need to be patient-centred, and yet there is a complete lack of qualitative research focused on this topic. By combining relevant published and grey literature we have provided a description of adult patients’ perceptions of response to biologicals in severe asthma. We now need to understand the views of children and adolescents with severe asthma and their carers, and diverse patient experiences in real-world settings.
脚注
这篇稿子最近已被接受发表在欧洲呼吸杂志.在我们的制作团队进行编辑和排版之前,它以被接受的形式发表在这里。在这些生产过程完成并且作者已经批准了产生的证明之后,文章将转移到最新的一期收获网上。请打开或下载PDF格式阅读本文。
利益冲突:所有作者报告称,欧洲肺基金会从欧盟委员会创新药物计划2联合项目(JU)获得了支持这项工作的资金,资助协议号为831434 (3TR)。没有进一步的披露。
这是一篇pdf格式的文章。请点击上面的PDF链接阅读。
- 收到了2022年4月21日。
- 接受2022年8月15日。
- 版权所有©作者2022。复制权限请联系权限在}{ersnet.org